Literature DB >> 5276777

Effects of L-dopa on norepinephrine metabolism in the brain.

J P Chalmers, R J Baldessarini, R J Wurtman.   

Abstract

Rats received intracisternal [(3)H]norepinephrine and, after 5 min, intraperitoneal L-dopa (100 mg/kg); they were killed at intervals during the subsequent 24 hr. Their brains were assayed for norepinephrine, L-dopa, S-adenosylmethionine, and [(3)H]norepinephrine and its metabolites. Rats that received L-dopa had markedly lower brain concentrations of S-adenosylmethionine and of O-methylated metabolites of [(3)H]norepinephrine than controls. An increase (15-40%) in brain norepinephrine content and accelerated turnover of brain norepinephrine was also observed in the animals receiving L-dopa. These changes were all transient, lasting about 1 hr and coinciding with the period when appreciable amounts of L-dopa were detectable in the brain.

Entities:  

Mesh:

Year:  1971        PMID: 5276777      PMCID: PMC389012          DOI: 10.1073/pnas.68.3.662

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Determination of catecholamines and catecholamino acids by differential spectrophotofluorimetry.

Authors:  T L SOURKES; G F MURPHY
Journal:  Methods Med Res       Date:  1961

2.  Dopa-induced excitement in the cat. Its relationship to brain norepinephrine concentrations.

Authors:  D J Reis; D T Moorhead; N Merlino
Journal:  Arch Neurol       Date:  1970-01

3.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

4.  L-dopa in idiopathic parkinsonism.

Authors:  D B Calne; G M Stern; A S Spiers; D R Laurence
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

Review 5.  Metabolism of norepinephrine in the central nervous system.

Authors:  J Glowinski; R J Baldessarini
Journal:  Pharmacol Rev       Date:  1966-12       Impact factor: 25.468

6.  Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain.

Authors:  J Constantinidis; G Bartholini; R Tissot; A Pletscher
Journal:  Experientia       Date:  1968-02-15

7.  L-dihydroxyphenylalanine: effect on S-adenosylmethionine in brain.

Authors:  R J Wurtman; S Matthysse; J Stephenson; R Baldessarini
Journal:  Science       Date:  1970-07-24       Impact factor: 47.728

8.  The effects of pentobarbital on the fate of intracisternally administered norepinephrine-H3.

Authors:  S M Schanberg; J J Schildkraut; I J Kopin
Journal:  J Pharmacol Exp Ther       Date:  1967-08       Impact factor: 4.030

9.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968

10.  L-Dopa-induced release of cerebral monoamines.

Authors:  K Y Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

View more
  13 in total

1.  L-dopa reverses behavioral deficits in the Pitx3 mouse fetus.

Authors:  Gale A Kleven; Heather M Booth; Marco Voogd; April E Ronca
Journal:  Behav Neurosci       Date:  2014-08-25       Impact factor: 1.912

2.  Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Authors:  P Riederer; W Birkmayer; D Seemann; S Wuketich
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

3.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

4.  L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans.

Authors:  R Surtees; K Hyland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

5.  Copper-mediated DNA damage by the neurotransmitter dopamine and L-DOPA: A pro-oxidant mechanism.

Authors:  Nida Rehmani; Atif Zafar; Hussain Arif; Sheikh Mumtaz Hadi; Altaf A Wani
Journal:  Toxicol In Vitro       Date:  2017-01-28       Impact factor: 3.500

6.  The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

Authors:  S Bergmann; G Curzon; J Friedel; R B Godwin-Austen; C D Marsden; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

7.  L-Dopa feeding suppression: effect on catecholamine neurons of the perifornical lateral hypothalamus.

Authors:  S F Leibowitz; C Rossakis
Journal:  Psychopharmacology (Berl)       Date:  1979-03-28       Impact factor: 4.530

8.  Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Authors:  Christian Pifl; Stephen J Kish; Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

9.  Modification of dopamine and norepinephrine metabolism in the rat brain by monoamine oxidase inhibitors.

Authors:  N T Buu; M Angers; J Duhaime; O Kuchel
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

10.  Stiff man syndrome in a black girl.

Authors:  H Isaacs
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.